Mantle Cell Lymphoma Highlights From the 2019 ASH Annual Meeting

Peter Martin, MD


January 03, 2020

Dr Peter Martin, from Weill Cornell Medicine in New York, reports on advances in mantle cell lymphoma (MCL) therapies from ASH 2019. In front-line treatment of older patients, the E1411 study looked at the addition of bortezomib to standard-induction bendamustine plus rituximab therapy. Concordant data from both molecular testing and flow cytometry demonstrated that approximately 90% of patients achieved negative minimal residual disease status by the end of cycle three.

Results of the GELTAMO study examining ibrutinib plus rituximab in low-risk patients suggest that chemotherapy may not be indicated in all MCL patients, though longer follow-up will be required.

From the ZUMA-2 trial, Dr Martin reports on promising data for CAR T-cell therapy following administration of BTK inhibitors. Complete responses were seen in approximately 50% of patients. However, the adverse event profile remains challenging.

From the poster session, Dr Martin discusses a study from the European Mantle Cell Lymphoma Network that compared data from two large phase 3 trials that could help clinicians better define biological high-risk populations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.